Galen Limited

Seagoe Industrial Estate, Craigavon, Co Armagh, Northern Ireland, BT63 5UA, Ireland
Telephone: +44 (0)28 3833 4974
Fax: +44 (0)28 3835 0206
WWW: http://www.galen.co.uk
Medical Information e-mail: customer.services@galen.co.uk

Summary of Product Characteristics last updated on the eMC: 10/06/2008
SPC Solvazinc


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Solvazinc® Effervescent Tablets.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each Solvazinc® tablet contains the following active ingredient: Zinc sulphate monohydrate: 125mg (equivalent to 45mg elemental zinc).


Go to top of the page
3. PHARMACEUTICAL FORM

Effervescent tablet.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Zinc sulphate is a source of zinc which is an essential trace element and involved in a number of body enzyme systems.

Indications: For the treatment of zinc deficiency.


Go to top of the page
4.2 Posology and method of administration

Method of Administration: oral after dissolution in water.

Adults: One tablet, dissolved in water, once to three times daily after meals.

Children: More than 30kg: One tablet, dissolved in water, once to three times daily after meals.

10-30kg: ½ tablet, dissolved in water, once to three times daily after meals.

Less than 10kg: ½ tablet, dissolved in water, once daily after meals.


Go to top of the page
4.3 Contraindications

None.


Go to top of the page
4.4 Special warnings and precautions for use

Accumulation of zinc may occur in cases of renal failure.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Zinc may inhibit the absorption of concurrently administered tetracyclines; when both are being given an interval of at least three hours should be allowed.


Go to top of the page
4.6 Pregnancy and lactation

The safety of this product in human pregnancy has not been established. Zinc crosses the placenta and is present in breast milk.


Go to top of the page
4.7 Effects on ability to drive and use machines

Solvazinc® is not expected to affect ability to drive and use machines.


Go to top of the page
4.8 Undesirable effects

Zinc salts may cause abdominal pain and dyspepsia.


Go to top of the page
4.9 Overdose

Zinc sulphate is corrosive in overdosage. Symptoms are corrosion and inflammation of the mucous membrane of the mouth and stomach; ulceration of the stomach followed by perforation may occur. Gastric lavage and emesis should be avoided. Demulcents such as milk should be given. Chelating agents such as sodium calcium edetate may be useful.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Zinc is an essential trace element involved in many enzyme systems. Severe deficiency causes skin lesion, alopecia, diarrhoea, increased susceptibility to infections and failure to thrive in children. Symptoms of less severe deficiency include distorted or absent perceptions of taste and smell and poor wound healing.


Go to top of the page
5.2 Pharmacokinetic properties

Zinc is absorbed from the gastrointestinal tract and distributed throughout the body. The highest concentrations occur in hair, eyes, male reproductive organs and bone. Lower levels are present in liver, kidney and muscle. In blood 80% is found in erythrocytes. Plasma zinc levels range from 70 to 110μg/dL and about 50% of this is loosely bound to albumin. About 7% is amino-acid bound and the rest is tightly bound to alpha 2-macroglobulins and other proteins.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Solvazinc® contains the following excipients:

Sorbitol, mannitol, sodium hydrogen carbonate, citric acid, saccharin sodium, povidone K25, sodium citrate and sodium carbonate anhydrous.


Go to top of the page
6.2 Incompatibilities

None.


Go to top of the page
6.3 Shelf life

Three years.


Go to top of the page
6.4 Special precautions for storage

Store below 25oC, protect from moisture.


Go to top of the page
6.5 Nature and contents of container

Polypropylene containers with polyethylene caps and packed in cartons of three containers. Each tablet container contains 30 tablets. The tablet containers also contain a desiccant capsule.


Go to top of the page
6.6 Special precautions for disposal and other handling

None.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Galen Limited

Seagoe Industrial Estate

Craigavon

BT63 5UA

UK


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 27827/0003.


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

01 November 1983.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

01 April 2008.



More information about this product

Link to this document from your website: http://emc.medicines.org.uk/medicine/452/SPC/Solvazinc/

Active Ingredients/Generics

 
   zinc sulphate monohydrate


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk